RECRUITINGOBSERVATIONAL
Prognostic Markers for a Better Follow-up in Head and Neck Cancer.
About This Trial
To identify tumor specific DNA mutations and aberrations and to follow these in blood over time to predict treatment response/survival and secondly to correlate presence of these markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological findings and to tumor stage.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patient diagnosed with head and neck cancer
- Treatment includes surgery
- Consent to participate
Who Should NOT Join This Trial:
- No consent
- Age below 18 years
- No surgery
- No tumor material to sample
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patient diagnosed with head and neck cancer
* Treatment includes surgery
* Consent to participate
Exclusion Criteria:
* No consent
* Age below 18 years
* No surgery
* No tumor material to sample
Treatments Being Tested
GENETIC
DNA exome sequencing of tumor and blood
A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
Locations (1)
Karolinska universitetssjukhuset
Stockholm, Sweden